|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/16/2013 7:37:49 AM
Last August, Bristol-Myers Squibb ended development of a hepatitis C compound after one patient died of heart failure and nine others were hospitalized during a Phase II study. The move was a huge blow to the drugmaker, which had recently paid $2.5 billion in cash for Inhibitex and its experimental medicine in hopes of grabbing a big chunk of the fast-growing market for hepatitis C treatments. Now, the other shoe is dropping. Having already taken a $1.8 billion charge for the spectacular flop, Bristol-Myers is holding talks with attorneys for several people who say they were injured as a result of participating in the failed study, and the costs and damages for claims could total $500 million, according to The Wall Street Journal. Four trial participants have filed lawsuits and 10 more are expected. In one lawsuit, Janet Vella of Corpus Christi, Texas, maintains that Bristol-Myers (BMY) rushed the compound to Phase II clinical trials “without fully evaluating the risks and benefits of the drug.” The drugmaker “pushed ahead with the clincal trials, despite clear signs of heart damage for those enrolled in the trials.” She was also instructed to remain in the trial after a diagnostic test revealed possible heart damage, her lawsuit states.
|
|
|
|
|
|
|
|
|
|
|